 At each visit, review of the internet survey use and medication weights will be done. Disease severity measures CEA, PSA, lesion counts will be obtained. Investigator and subject VAS scales to measure facial erythema will be obtained. Adverse events will be logged at every visit. Attention will be paid to any symptoms of rebound erythema and more detailed information concerning location and timing will be collected. The lesion counts will also measure any papules or telangiectasia that may become more readily visible with the improvement in background erythema. Telangiectasia will be counted individually by facial quadrant as noted in the Lesion Count Appendix. Measuring individual visible telangiectasia is important as subjects may confuse these with underlying erythema of rosacea, thus affecting subject assessment of their disease. QOL surveys will be completed at the end of study visit. 